HEY2 Regulation of Cardiac Mitochondrial Metabolism and Homeostasis

Study Background and Research Question

Heart failure (HF) remains a major cause of morbidity and mortality worldwide, marked by impaired contractility and compromised cardiac output. Central to HF pathophysiology is the energy deprivation of cardiomyocytes, primarily driven by mitochondrial dysfunction. Healthy adult hearts rely heavily on mitochondrial oxidative phosphorylation, fueled by fatty acid oxidation, to meet high ATP demands. In heart failure, this metabolic profile shifts toward glycolysis, but the molecular regulators orchestrating this shift and their impact on cardiac homeostasis are not fully understood. The reference study investigates the role of the transcriptional repressor HEY2 in regulating mitochondrial energy metabolism, aiming to delineate its function in maintaining cardiac health and its implications in heart failure progression.

Key Innovation from the Reference Study

The innovation of this research lies in identifying HEY2 as a conserved transcriptional regulator that acts directly at the promoters of genes essential for mitochondrial oxidative metabolism. The study demonstrates that HEY2 exerts its influence through interaction with histone deacetylase HDAC1, resulting in transcriptional repression of PPARGC1A (PGC-1α), ESRRA, and CPT1, key drivers of mitochondrial biogenesis and fatty acid oxidation. By modulating this HEY2/HDAC1–PPARGC1/ESRRA axis, the research uncovers a mechanistic link between transcriptional repression and the metabolic reprogramming observed in heart failure.

Methods and Experimental Design Insights

The study employs a multifaceted experimental approach across model systems. First, the authors analyzed heart tissue from patients with dilated cardiomyopathy, noting HEY2 upregulation. To probe causal relationships, they utilized zebrafish and mouse cardiac models for both overexpression and knockdown of Hey2. In zebrafish hearts and mammalian cardiomyocytes, induced Hey2 expression impaired mitochondrial respiration, increased reactive oxygen species (ROS), and promoted apoptosis. Conversely, Hey2 depletion in adult mouse and zebrafish hearts enhanced mitochondrial gene expression and improved cardiac function.

Genome-wide chromatin immunoprecipitation (ChIP) and RNA sequencing were used to map HEY2 binding and transcriptional consequences. Co-immunoprecipitation revealed HEY2 colocalizes with HDAC1 at promoters of metabolic genes. Rescue experiments, restoring PPARGC1A/ESRRA activity in Hey2-overexpressing hearts, reversed mitochondrial bioenergetic deficits. Additionally, doxorubicin-induced cardiac dysfunction models confirmed that Hey2 knockdown confers protection against cardiotoxic stress.

Core Findings and Why They Matter

• HEY2 is upregulated in failing hearts: Both patient samples and animal models show increased HEY2 expression in the context of cardiac dysfunction (reference study).
• HEY2 represses key metabolic genes: Direct binding of HEY2 to the promoters of PPARGC1A, ESRRA, and CPT1 results in downregulation of mitochondrial oxidative genes, curbing fatty acid oxidation and ATP production.
• HEY2/HDAC1 complex mediates repression: The interaction with HDAC1 highlights an epigenetic mechanism, whereby histone deacetylation silences metabolic pathways critical for cardiac energy supply.
• Functional rescue is possible: Restoring PPARGC1A/ESRRA mitigates mitochondrial dysfunction and cardiac impairment caused by excessive HEY2, suggesting reversibility of the phenotype.
• Protective effect against cardiotoxicity: Knockdown of Hey2 in adult mouse hearts offers resistance to doxorubicin-induced cardiac dysfunction, supporting a potential therapeutic angle.

These findings clarify how metabolic gene expression is tightly regulated in the heart and how dysregulation contributes to the progression of heart failure. The identification of the HEY2/HDAC1–PPARGC1 axis as a pivotal control node opens new avenues for intervention in metabolic cardiomyopathies.

Comparison with Existing Internal Articles

While the reference study centers on transcriptional and epigenetic control of mitochondrial metabolism in cardiac tissue, internal resources such as "N1-Methylpseudouridine: Pioneering mRNA Modification for..." and "N1-Methylpseudouridine: Mechanistic Breakthroughs and Str..." focus on molecular tools—specifically, modified nucleosides like N1-Methylpseudouridine (N1mΨ)—that enhance mRNA translation and reduce immunogenicity in mammalian systems. Although these articles do not directly address energy metabolism or transcriptional repression in cardiac biology, they provide practical insights on optimizing mRNA-based research workflows, including studies involving gene regulation and protein expression in cardiac cells. For example, the ability of N1-Methylpseudouridine to increase mRNA translation efficiency and minimize innate immune activation is particularly relevant for gene therapy or regenerative medicine approaches targeting cardiac function, as discussed in the context of disease modeling and experimental interventions.

Limitations and Transferability

The study's strengths include the use of both human and animal models, comprehensive genomic mapping, and functional rescue experiments. However, several limitations should be noted. First, while zebrafish and mouse models faithfully recapitulate aspects of human cardiac biology, interspecies differences may affect the generalizability of findings. Second, the molecular mechanisms downstream of HEY2—beyond the repression of PPARGC1A/ESRRA—require further exploration, particularly in the context of chronic versus acute cardiac stress. Third, the study focuses on mitochondrial metabolism; extrapolation to other metabolic pathways or cell types should be approached cautiously. Finally, the translation of these findings into clinical therapies remains at a preclinical stage, necessitating further validation in human tissue and disease models.

Protocol Parameters

• HEY2 overexpression: Use tissue-specific promoters or viral vectors for targeted induction in cardiomyocytes; verify expression by qPCR or Western blot.
• HEY2 knockdown: Apply CRISPR/Cas9 or shRNA in adult mouse or zebrafish hearts; confirm knockdown efficiency prior to phenotypic assessment.
• Mitochondrial respiration assays: Isolate cardiomyocytes and utilize Seahorse XF Analyzer to measure oxygen consumption rates, ensuring adequate cell viability and normalization.
• Gene rescue experiments: Deliver PPARGC1A/ESRRA via mRNA or plasmid; monitor restoration of oxidative phosphorylation and ATP levels.
• Doxorubicin-induced cardiotoxicity: Administer doxorubicin intraperitoneally in adult mice; assess cardiac function by echocardiography and histological analysis post-treatment.

Research Support Resources

For researchers seeking to investigate transcriptional and translational regulation in cardiac or other mammalian systems, the use of modified nucleosides such as N1-Methylpseudouridine (SKU B8340) is recommended to enhance mRNA translation efficiency and reduce immunogenicity. This compound, available from APExBIO, is validated for use in multiple cell lines and supports robust protein expression in experimental workflows. For detailed scenario-based guidance on integrating N1-Methylpseudouridine into your protocols, see articles such as "Maximizing mRNA Translation: Practical Scenarios with N1-...".